Mind Cure Health Inc. (CSE: MCUR) has engaged Dr. Dan Engle as Primary Investigator Consultant for its research into psychedelic compounds for treating traumatic brain injury (TBI). Dr. Engle, a board-certified psychiatrist and neurologist, brings a wealth of experience from his clinical practice focused on functional medicine and neuro-cognitive restoration. The company identifies TBI as a priority due to its rising prevalence, with TBI-related emergency visits increasing by 53% from 2006 to 2014 in North America. Mind Cure aims to advance its TBI research from pre-clinical to clinical stages.
MINDCURE has successfully completed beta testing of its PsyCollage bioinformatics platform, reaching its Q1 milestone. This platform enhances drug lead optimization and the discovery of target receptors in psychedelic research. PsyCollage has identified key indications, including neuropathic pain and migraines, and aims to facilitate strategic partnerships. Additionally, 800,000 stock options were granted to employees at a price of $0.65 per share. The company is committed to innovating mental health care and addressing the urgent need for effective treatments.